Pairing a New Medicine with Enzalutamide for Advanced Prostate Cancer Treatment

Recruiting · Phase 3 · Metastatic Castration-Resistant Prostate Cancer · 11 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This study looks at how well the medicine PF-06821497, combined with enzalutamide, works for men with advanced prostate cancer. The goal is to see if this combination is more effective than using enzalutamide alone. This research involves men who have not received certain previous treatments for their cancer. It is designed to help improve options for treating metastatic castration-resistant prostate cancer, or mCRPC.

This is a Phase 3 trial, meaning it is looking at how well the treatment works and its safety. It is regulated by the FDA and aims to include around 900 participants.

Who can join

This trial is open to men ages 18 and older who have been diagnosed with advanced prostate cancer. To join, they should not have had specific treatments for their cancer before. Some health conditions, like certain heart problems or a history of serious illness, may prevent someone from participating. The trial team will check to see if each person is eligible.

Condition

Metastatic Castration-Resistant Prostate Cancer

Age group

Adult, Older adult

Sex

Male

The study team makes the final call on eligibility.

What happens in the study

Participants will be randomly assigned to one of two groups. One group (Arm A) will receive PF-06821497 along with enzalutamide. The other group (Arm B) will receive a placebo, which looks like the medicine but has no active ingredients, along with enzalutamide. Everyone will take their assigned treatment daily, with the study lasting several years.